â– LECTURE OVERVIEW: Cervical cancer develops via a predictable progression driven by chronic infection with high-risk strains of Human Papillomavirus (HPV).
â– THE MOLECULAR PATHWAYS:
1. High-Risk Strains: Primarily HPV strains 16 and 18.
2. Genomic Integration: The virus enters basal epithelial cells, integrating its circular DNA into the host genome, which triggers the overexpression of viral oncogenes E6 and E7.
3. E6 (p53 degradation): The E6 protein binds and targets the p53 tumor suppressor for ubiquitin-mediated proteasomal degradation, bypassing cell cycle arrest and apoptosis in response to DNA damage.
4. E7 (Rb inactivation): The E7 protein binds and hyperphosphorylates the Retinoblastoma (Rb) protein, releasing the E2F transcription factor. Constant E2F activity drives the cell into S-phase replication.
5. Transformation Zone: This neoplastic transformation occurs selectively at the squamocolumnar junction (transformation zone) of the cervix, where columnar epithelium undergoes squamous metaplasia.
â– EPIDEMIOLOGICAL PROFILE & PREVALENCE METRICS:
Global burden mapping indicates significant geographic, ethnic, and temporal patterns. Incidence statistics reveal correlation with environmental lifestyle stressors, socio-economic vectors, and genetic founder effects.
â– SECONDARY PREVENTION METRICS:
Implementing long-term dietary adaptations, physical therapy, and compliance aids reduces the rate of recurring acute crises by more than half.
[HY-BOARD-1235]
🌟 Dynamic Clinical Key:
Cervical cancer is highly preventable via Pap smear screening (which cytologically identifies dysplasia before it becomes invasive cancer) and the recombinant HPV vaccine, which target major high-risk viral capsid antigens. Utilize standardized screening questionnaires across highly endemic populations to detect early subclinical cases. Patient education regarding warning signs and therapy adherence is the cornerstone of secondary prevention.